多发性骨髓瘤长期生存的分子与免疫决定因素
本文综述多发性骨髓瘤(MM)长期生存(LTS,定义为诊断后单线治疗存活≥10年)的分子与免疫决定因素,指出蛋白酶体抑制剂、免疫调节药物、单克隆抗体、自体干细胞移植及新型免疫治疗改善了MM治疗,但仅部分患者获得长期疾病控制,提示骨髓瘤内在与免疫介导机制均起关键作用。
要点
- LTS定义为诊断后接受单线治疗存活≥10年,随治疗进步日益常见。
- 仅部分患者获得长期持久疾病控制,提示骨髓瘤内在与免疫介导机制均关键。
- 免疫骨髓微环境(IBME)中T细胞功能增强、NK细胞毒性增加及免疫抑制性髓系群体减少与疾病控制相关。
核心结论
- 理解LTS MM中的免疫适应为开发下一代治疗策略提供基础。
- 未来整合基因组与免疫分析及IBME调节的研究,对将MM治疗范式从疾病管理转向持续缓解和功能性治愈至关重要。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 蛋白酶体抑制剂、免疫调节药物、单克隆抗体、自体干细胞移植和新型免疫治疗的应用改变了MM治疗。
- 嵌合抗原受体T细胞疗法和双特异性抗体等治疗进展主要使标危患者获益。
- LTS似乎由免疫骨髓微环境(IBME)的独特特征驱动,其中T细胞功能增强、自然杀伤细胞毒性增加和免疫抑制性髓系群体减少有助于疾病控制。
关键数值与推荐
- LTS定义为诊断后接受单线治疗存活≥10年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-term survival (LTS) in multiple myeloma (MM), defined as survival of ≥10 years after diagnosis following a single line of therapy, is an increasingly observed outcome due to significant therapeutic advancements. The introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, autologous stem cell transplantation, and novel immunotherapies has transformed MM treatment. Importantly, only a subset of patients achieves long-term, durable disease control, suggesting that both myeloma-intrinsic and immune-mediated mechanisms play critical roles. Therapeutic advancements, including chimeric antigen receptor T-cell therapy and bispecific antibodies, have primarily benefited standard-risk patients. Beyond therapeutic interventions, LTS appears to be driven by distinct features of the immune bone marrow environment (IBME), in which enhanced T-cell function, increased natural killer cell cytotoxicity, and reduced immunosuppressive myeloid populations contribute to disease control. Understanding these immune adaptations in LTS MM provides a foundation for developing next-generation treatment strategies. Future research integrating genomic and immune profiling, along with IBME modulation, will be critical in shifting MM treatment paradigms from disease management to sustained remission and functional cures.
引用
- Kasomva K, Yadav K, Janz S, et al. Molecular and immunological determinants of long-term survival in multiple myeloma. Blood Adv. 2025. PMID: 40674709. doi:10.1182/bloodadvances.2025016829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。